Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Iscience|October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activityElizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Vaccines|October 28, 2025
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient TransfectionAgnes Hajduczki, William C Chang, Rafael De La Barrera, et al.
Cell Reports. Medicine|April 6, 2023
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaquesJingyou Yu, Paul V Thomas, Michaela Sciacca, et al.
Science Advances|November 23, 2022
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFNJingyou Yu, Paul V Thomas, Katherine McMahan, et al.
Nature Communications|February 3, 2023
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivityWei-Hung Chen, Agnes Hajduczki, Elizabeth J Martinez, et al.
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Vaccines|May 28, 2022
A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) ModelSara C Johnston, Keersten M Ricks, Ines Lakhal-Naouar, et al.
Nature Immunology|October 30, 2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsVincent Dussupt, Rajeshwer S Sankhala, Letzibeth Mendez-Rivera, et al.
Pageof 3